Published in Ann Neurol on March 17, 2011
Compulsive features in behavioural addictions: the case of pathological gambling. Addiction (2011) 3.28
Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. Neurology (2014) 2.64
Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study. Neurology (2013) 2.24
Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. Neurology (2013) 1.56
Neuropsychological features of patients with Parkinson's disease and impulse control disorders. Neurol Sci (2012) 1.47
Nonmotor symptoms in Parkinson's disease in 2012: relevant clinical aspects. Parkinsons Dis (2012) 1.12
Impulse control disorders in Parkinson's disease: recent advances. Curr Opin Neurol (2011) 1.11
Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: a [11C] FLB-457 and PET study. Neurobiol Dis (2012) 1.05
Should Hypersexual Disorder be Classified as an Addiction? Sex Addict Compulsivity (2013) 1.05
Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease. Rev Neurosci (2013) 1.03
Gambling disorder and other behavioral addictions: recognition and treatment. Harv Rev Psychiatry (2015) 1.03
Effects of STN and GPi deep brain stimulation on impulse control disorders and dopamine dysregulation syndrome. PLoS One (2012) 0.97
Personality traits in patients with Parkinson's disease: assessment and clinical implications. J Neurol (2011) 0.96
The functional anatomy of impulse control disorders. Curr Neurol Neurosci Rep (2013) 0.94
Relations among delay discounting, addictions, and money mismanagement: implications and future directions. Am J Drug Alcohol Abuse (2012) 0.94
Uncertainty about mapping future actions into rewards may underlie performance on multiple measures of impulsivity in behavioral addiction: evidence from Parkinson's disease. Behav Neurosci (2013) 0.92
Health-related quality of life in Parkinson's disease: a cross-sectional study focusing on non-motor symptoms. Health Qual Life Outcomes (2015) 0.90
Management of sexual dysfunction in Parkinson's disease. Ther Adv Neurol Disord (2011) 0.90
Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease. Brain (2014) 0.89
Prospective cohort study of impulse control disorders in Parkinson's disease. Mov Disord (2013) 0.88
Impulsivity and apathy in Parkinson's disease. J Neuropsychol (2013) 0.87
Parkinson disease: impulsive choice-Parkinson disease and dopaminergic therapy. Nat Rev Neurol (2011) 0.85
Linking neuroscience with modern concepts of impulse control disorders in Parkinson's disease. Mov Disord (2014) 0.85
Pathological choice: the neuroscience of gambling and gambling addiction. J Neurosci (2013) 0.84
Impulse control disorders in Parkinson's disease: the role of personality and cognitive status. J Neurol (2012) 0.83
Imaging impulse control disorders in Parkinson's disease and their relationship to addiction. J Neural Transm (Vienna) (2012) 0.83
A new approach to assess gambling-like behavior in laboratory rats: using intracranial self-stimulation as a positive reinforcer. Front Behav Neurosci (2014) 0.83
Genetics of impulse control disorders in Parkinson's disease. J Neural Transm (Vienna) (2012) 0.83
Impulsive and compulsive behaviors in Parkinson's disease. Annu Rev Clin Psychol (2013) 0.82
Impulse control disorders in Parkinson's disease: decreased striatal dopamine transporter levels. J Neurol Neurosurg Psychiatry (2013) 0.82
Impulsive and compulsive behaviors in Parkinson's disease. Front Aging Neurosci (2014) 0.82
An exploration of apathy and impulsivity in Parkinson disease. Curr Gerontol Geriatr Res (2012) 0.80
Diagnosis and treatment of impulse control disorders in patients with movement disorders. Ther Adv Neurol Disord (2013) 0.80
Novelty, conditioning and attentional bias to sexual rewards. J Psychiatr Res (2015) 0.79
Ventral striatal dopamine synthesis capacity predicts financial extravagance in Parkinson's disease. Front Psychol (2013) 0.79
Impulse control disorders in Parkinson's disease: background and update on prevention and management. Neurodegener Dis Manag (2012) 0.79
Frontostriatal cognitive staging in Parkinson's disease. Parkinsons Dis (2011) 0.79
Trends and issues in characterizing early cognitive changes in Parkinson's disease. Curr Neurol Neurosci Rep (2012) 0.78
Parallel appearance of compulsive behaviors and artistic creativity in Parkinson's disease. Case Rep Neurol (2012) 0.78
Betting on DBS: Effects of subthalamic nucleus deep brain stimulation on risk taking and decision making in patients with Parkinson's disease. Neuropsychology (2014) 0.78
Sleep and impulsivity in Parkinson's disease. Parkinsonism Relat Disord (2013) 0.78
Pramipexole-induced disruption of behavioral processes fundamental to intertemporal choice. J Exp Anal Behav (2013) 0.77
Single versus multiple impulse control disorders in Parkinson's disease: an ¹¹C-raclopride positron emission tomography study of reward cue-evoked striatal dopamine release. J Neurol (2015) 0.77
Clinical characteristics of impulse control and repetitive behavior disorders in Parkinson's disease. J Neurol (2012) 0.77
Clinical-genetic model predicts incident impulse control disorders in Parkinson's disease. J Neurol Neurosurg Psychiatry (2016) 0.76
Jumping to conclusions in untreated patients with Parkinson's disease. Neuropsychologia (2016) 0.76
Pharmacologically distinct pramipexole-mediated akinesia vs. risk-taking in a rat model of Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry (2016) 0.76
Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease. J Neurol (2012) 0.76
Molecular imaging and neural networks in impulse control disorders in Parkinson's disease. Parkinsonism Relat Disord (2015) 0.76
Maladaptive reward-learning and impulse control disorders in patients with Parkinson's disease: a clinical overview and pathophysiology update. J Mov Disord (2014) 0.76
Pramipexole Increases Go Timeouts but Not No-go Errors in Healthy Volunteers. Front Hum Neurosci (2016) 0.75
Impulsive and Compulsive Behaviors in Parkinson Disease: The Norwegian ParkWest Study. J Parkinsons Dis (2016) 0.75
Effects of Night-Time Use of Rotigotine on Nocturnal Symptoms in Parkinson's Disease. Parkinsons Dis (2015) 0.75
Dopaminergic and clinical correlates of pathological gambling in Parkinson's disease: a case report. Front Behav Neurosci (2013) 0.75
Neuropsychiatric symptoms in untreated Parkinson's disease. Neuropsychiatr Dis Treat (2017) 0.75
Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease. J Neurol Neurosurg Psychiatry (2015) 0.75
A conditioned response as a measure of impulsive-compulsive behaviours in Parkinson's disease. PLoS One (2014) 0.75
Quality improvement in neurology: Parkinson disease update quality measurement set: Executive summary. Neurology (2016) 0.75
Impulsivity is Associated with Increased Metabolism in the Fronto-Insular Network in Parkinson's Disease. Front Behav Neurosci (2015) 0.75
Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis. Eur J Neurol (2016) 0.75
Hospital care for mental health and substance abuse conditions in Parkinson's disease. Mov Disord (2016) 0.75
Impact of Impulse Control Disorders on Sleep-Wake Regulation in Parkinson's Disease. Parkinsons Dis (2015) 0.75
Deep-Brain Stimulation of the Subthalamic Nucleus Selectively Decreases Risky Choice in Risk-Preferring Rats. eNeuro (2017) 0.75
Executive functioning and risk-taking behavior in Parkinson's disease patients with impulse control disorders. J Neural Transm (Vienna) (2016) 0.75
Impaired learning of punishments in Parkinson's disease with and without impulse control disorder. J Neural Transm (Vienna) (2016) 0.75
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med (2006) 10.89
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
Developmental neurocircuitry of motivation in adolescence: a critical period of addiction vulnerability. Am J Psychiatry (2003) 7.11
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
Can food be addictive? Public health and policy implications. Addiction (2011) 6.27
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol (2006) 5.49
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord (2012) 5.12
Phenomenology and classification of dystonia: a consensus update. Mov Disord (2013) 4.98
Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol (2010) 4.77
From psychogenic movement disorder to functional movement disorder: it's time to change the name. Mov Disord (2013) 4.77
Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord (2003) 4.56
Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA (2002) 4.38
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2010) 3.84
Mutations in GNAL cause primary torsion dystonia. Nat Genet (2012) 3.66
Behavioral impulsivity predicts treatment outcome in a smoking cessation program for adolescent smokers. Drug Alcohol Depend (2006) 3.61
Compulsive features in behavioural addictions: the case of pathological gambling. Addiction (2011) 3.28
Introduction to behavioral addictions. Am J Drug Alcohol Abuse (2010) 3.22
Cognitive impairment and PD patients' capacity to consent to research. Neurology (2013) 3.22
Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol (2003) 3.22
Dependence of subthalamic nucleus oscillations on movement and dopamine in Parkinson's disease. Brain (2002) 3.15
Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology (2006) 3.10
Criteria for the diagnosis of corticobasal degeneration. Neurology (2013) 3.07
Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol (2006) 3.02
Hemiballism: revisiting a classic disorder. Lancet Neurol (2003) 3.00
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol (2003) 2.93
Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease. Neurology (2015) 2.88
Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol (2008) 2.79
Stereotypies: a critical appraisal and suggestion of a clinically useful definition. Mov Disord (2011) 2.76
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol (2010) 2.67
A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain (2008) 2.65
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Mov Disord (2014) 2.64
Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord (2007) 2.62
Probing compulsive and impulsive behaviors, from animal models to endophenotypes: a narrative review. Neuropsychopharmacology (2009) 2.60
Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord (2006) 2.53
Mindfulness-based treatments for co-occurring depression and substance use disorders: what can we learn from the brain? Addiction (2010) 2.50
Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry (2006) 2.50
Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol (2009) 2.46
Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol (2007) 2.40
Preliminary validity and reliability testing of a structured clinical interview for pathological gambling. Psychiatry Res (2004) 2.35
Cue-induced brain activity changes and relapse in cocaine-dependent patients. Neuropsychopharmacology (2006) 2.32
Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker. Mov Disord (2013) 2.32
Conversion between mini-mental state examination, montreal cognitive assessment, and dementia rating scale-2 scores in Parkinson's disease. Mov Disord (2014) 2.30
Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations. Mov Disord (2008) 2.28
MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord (2011) 2.27
Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol (2010) 2.26
Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. Ann Neurol (2003) 2.23
The neurobiology and genetics of impulse control disorders: relationships to drug addictions. Biochem Pharmacol (2007) 2.22
Stimulation of the subthalamic nucleus in Parkinson's disease does not produce striatal dopamine release. Neurosurgery (2003) 2.21
Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord (2010) 2.20
Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol (2010) 2.20
Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord (2004) 2.19
Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology (2012) 2.18
Beta oscillatory activity in the subthalamic nucleus and its relation to dopaminergic response in Parkinson's disease. J Neurophysiol (2006) 2.18
Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov Disord (2012) 2.18
Individuals family history positive for alcoholism show functional magnetic resonance imaging differences in reward sensitivity that are related to impulsivity factors. Biol Psychiatry (2010) 2.16
Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification. Neurogenetics (2013) 2.11
Broadening our horizon: response to commentaries. Addiction (2012) 2.11
Impulse control disorders in adult psychiatric inpatients. Am J Psychiatry (2005) 2.09
Health correlates of recreational gambling in older adults. Am J Psychiatry (2004) 2.08
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord (2011) 2.05
Pretreatment brain activation during stroop task is associated with outcomes in cocaine-dependent patients. Biol Psychiatry (2008) 2.04
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol (2004) 2.02
Short and long latency afferent inhibition in Parkinson's disease. Brain (2003) 2.02
Gender differences in the associations between past-year gambling problems and psychiatric disorders. Soc Psychiatry Psychiatr Epidemiol (2007) 2.02
Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. J Neurosurg (2003) 2.01
Bilateral globus pallidus stimulation for Huntington's disease. Ann Neurol (2004) 2.00
Analysis of the glucocerebrosidase gene in Parkinson's disease. Mov Disord (2005) 1.99
A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease. Mov Disord (2008) 1.98
Montreal cognitive assessment performance in patients with Parkinson's disease with "normal" global cognition according to mini-mental state examination score. J Am Geriatr Soc (2008) 1.92
Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology (2012) 1.91
Investigating the behavioral and self-report constructs of impulsivity domains using principal component analysis. Behav Pharmacol (2009) 1.90
Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease. Mov Disord (2009) 1.89
Update on blepharospasm: report from the BEBRF International Workshop. Neurology (2008) 1.87
Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol (2007) 1.86
Levodopa response in long-term bilateral subthalamic stimulation for Parkinson's disease. Mov Disord (2007) 1.82
Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol (2013) 1.82
Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications. JAMA Neurol (2013) 1.81
Psychogenic movement disorders. Curr Opin Neurol (2009) 1.81
Overview of the extranigral aspects of Parkinson disease. Arch Neurol (2009) 1.79
Similarities and differences between pathological gambling and substance use disorders: a focus on impulsivity and compulsivity. Psychopharmacology (Berl) (2011) 1.77
Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol (2010) 1.77
Problematic Internet use: clinical implications. CNS Spectr (2007) 1.74
Premotor Parkinson's disease: concepts and definitions. Mov Disord (2012) 1.70
An FMRI study of the effects of psychostimulants on default-mode processing during Stroop task performance in youths with ADHD. Am J Psychiatry (2009) 1.70
Psychiatric correlates of gambling in adolescents and young adults grouped by age at gambling onset. Arch Gen Psychiatry (2004) 1.68